IP Library › Granted Patent US 12,655,388
Granted Patent B2
US 12,655,388 · App. 17/626,990 · Granted Jun 16, 2026

Virus-like particle

Inventors: Abigail Culshaw (London, GB); Rosie Woodruff (London, GB); Alexander Burkard (London, GB); Martin Madill (London, GB)
Assignee: AUTOLUS LIMITED
C12N5/0636A61K40/11A61K40/31A61K40/4211A61K40/4212C12N5/0638C12N5/0687C12N15/625C12N15/85C12N15/86C12N2501/2307C12N2501/2315C12N2740/10022C12N2740/10023C12N2740/10043C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,388
App. No.
17/626,990
Granted
Jun 16, 2026
Kind
B2
Abstract

The present invention provides a virus-like particle (VLP) having a viral envelope which comprises: (i) a membrane protein comprising the extracellular domain of CD86; and (ii) a CD3-binding membrane protein. The VLP may be used to activate T cells prior to viral transduction.

Claims (12)

1 . A virus-like particle (VLP) having a viral envelope which comprises:

(i) a membrane protein comprising the extracellular domain of CD86 and the transmembrane domain of CD8, wherein the membrane protein comprises an amino acid sequence according to SEQ ID NO: 15; and

(ii) a CD3-binding transmembrane protein.

2 . The VLP according to claim 1 , which is a retroviral-derived or lentiviral-derived VLP.

3 . The VLP according to claim 1 , which is derived from Moloney murine leukemia virus (Mo-MLV).

4 . The VLP according to claim 1 , wherein the CD3-binding transmembrane protein comprises an OKT3-derived antigen binding domain.

5 . A nucleic acid construct which comprises a first nucleic acid sequence encoding a membrane protein comprising the extracellular domain of CD86 and the transmembrane domain of CD8, wherein the membrane protein comprises an amino acid sequence according to SEQ ID NO: 15; and a second nucleic acid sequence encoding a CD3-binding transmembrane protein.

6 . A vector comprising a nucleic acid construct according to claim 5 .

7 . A kit of vectors which comprises:

(i) a first vector which comprises a nucleic acid sequence encoding a membrane protein comprising the extracellular domain of CD86 and the transmembrane domain of CD8, wherein the membrane protein comprises an amino acid sequence according to SEQ ID NO: 15; and (ii) a second vector which comprises a nucleic acid sequence encoding a CD3-binding transmembrane protein.

8 . A method for activating a T cell which comprises the step of culturing the T cell in the presence of a VLP according to claim 1 .

9 . A method according to claim 8 , wherein the T cell is also cultured in the presence of IL-7 or IL-15.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2022
From: CULSHAW, ABIGAIL; WOODRUFF, ROSIE; BURKARD, ALEXANDER; MADILL, MARTIN
To: AUTOLUS LIMITED
Reel/Frame 059356/0900 →
Priority Claims (1)
GB 1910651 · Jul 25, 2019 · national
Continuity (1)
Related Publication 20220249566A1 · Aug 11, 2022
References Cited (15)
US 10745715B2 · Pule et al. · 2020 [cited by applicant]
US 20060205069A1 · June et al. · 2006 [cited by applicant]
US 20140308308A1 · Anderson · 2014 [cited by examiner]
US 20150071987A1 · Selvaraj · 2015 [cited by applicant]
US 20180311374A1 · Lobb · 2018 [cited by examiner]
US 20190177746A1 · Peddareddigari et al. · 2019 [cited by applicant]
WO WO2016030690A1 · 2016 [cited by applicant]
WO WO2016102965A1 · 2016 [cited by applicant]
WO WO2016135470A1 · 2016 [cited by applicant]
WO WO2018009923A1 · 2018 [cited by applicant]
WO WO2018033726A1 · 2018 [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB2020/051777, mailed Jan. 18, 2021, 12 Pages. [cited by applicant]
Maurice et al., “Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide,” Blood 99:2342-2350 (2002). [cited by applicant]
Mosca et al., “Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents,” Retrovirology 4:32, 18 pages (2007). [cited by applicant]
Paszkiet et al., “CD86 and CD54 Co-Expression on VSV-G Pseudotyped HIV-1 Based Vectors Improves Transduction and Activation of Human Primary CD4+ Lymphocytes,” Blood 104(11):1754, 5 pages (2004). [cited by applicant]